Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis

Experimental Cell Research

Volumn 317, Issue 9, 2011, Pages 1286-1292

  Mircic, Maja ^a   Kavanaugh, Arthur ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

IL6R inhibitors; Juvenile idiopathic arthritis; Rheumatoid arthritis; Tocilizumab

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TOCILIZUMAB;

ANGIONEUROTIC EDEMA; BACTERIAL ARTHRITIS; CHICKENPOX; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; IDIOPATHIC DISEASE; IMMUNOTHERAPY; JOINT RADIOGRAPHY; JUVENILE RHEUMATOID ARTHRITIS; MONOTHERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA;

EID: 79955670864     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2011.02.017     Document Type: Review

References (15)

1. Yoshizaki K., Nishimoto N., Mihara M., Kishimoto T. Therapy of rheumatoid arthritis by blocking Il-6 signal transduction with humanized anti Il-6 receptor antibody. Springer Semin. Immunopathol. 1998, 20(1-2):247-259.
2. Nishimoto N., Yoshizaki K., Maeda K. Toxicity, pharmacokinetics and dose finding study of repetitive treatment with the humanized anti-interleukin-6 receptor antibody MRA in rheumatoid arthritis. J. Rheumatol. 2003, 30(7):1426-1435.
3. Oldfield V., Dhillon S., Plosker G.L. Drugs 2009, 69(5):609-632. 10.2165/00003495-200969050-00007.
4. Smolen J., Beaulieu A., Rubbert-Roth A. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008, 371(9617):987-997.
5. Genovese M., McKay J., Nasonov E. il-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2008, 58(10):2968-2980.
6. Nishimoto N., Hashimoto J., Miyasaka N. Study of active controlled monotherapy used for rheumatoid arthritis, and IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomized controlled trial of tocilizumab. Ann. Rheum. Dis. 2007, 66(9):1162-1167.
7. Emery P., Keystone E., Tony H.P. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 2008, 67(11):1516-1523.
8. Nishimoto N., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Azuma J., Kishimoto T. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod. Rheumatol. 2009, 19(1):12-19.
9. Nishimoto N., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Azuma J. Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis(the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann. Rheum. Dis. 2008, Nov 19 (Epub ahead of print).
10. Fleischmann R., Burgos-Vargas R., Skopouli F.N. Tocilizumab inhibits radiographic progression, improves physical function, and gains efficacy over time: LITHE 2year. Ann. Rheum. Dis. 2010, 69(Suppl 3):384.
11. Yokota S., Imagawa T., Mori M., Miyamae T., Aihara Y., Takei S., Iwata N., Umebayashi H., Murata T., Miyoshi M., Tomiita M., Nishimoto N., Kishimoto T. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double blind, placebo-controlled, withdrawal phase III trial. Lancet Mar 22 2008, 371(9617):998-1006.
12. De Benedetti F., Brunner H., Ruperto N., Wright S., Kenwright A., Cuttica R., Woo P., Schneider R., Lovell D., Martini A. From biology to classification and targeted therapy in Juvenile Idiopathic. Arthritis Ann. Rheum. Dis. 2010, 69(Suppl 3):146.
13. Choy E.H.S., Isenberg D.A., Garrood T. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. A randomized, double-blind, placebo-controlled, dose escalation trial. Arthritis Rheum. 2002, 46(12):3143-3150.
14. Nishimoto N., Yoshizaki K., Miyasaka N. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multi-center, double-blind, placebo-controlled trial. Arthritis Rheum. 2004, 50(6):1761-1769.
15. Maini R.N., Taylor P.C., Szechinski J. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006, 54(9):2817-2829.